Closed · PAR-11-151 · CFDA 93.394;93.395 · Discretionary

Strategic Partnering to Evaluate Cancer Signatures [SPECS II] (U01)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $680K
Award range
Closed
Status
June 15, 2012
Close date
-
Expected awards

The verdict

Strategic Partnering to Evaluate Cancer Signatures [SPECS II] (U01) is a closed discretionary listing from National Institutes of Health that offered Up to $680,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $680K
award range
Closed
application status
93.394;93.395
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Strategic Partnering to Evaluate Cancer Signa… is closed (last close June 15, 2012). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed June 15, 2012

Posted Mar 14 Closes Jun 15

Instrument

Cooperative Agreement

Description

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI) of the National Institutes of Health (NIH), encourages the submission of grant applications for support of the clinical application of multi-analyte molecular signatures derived from comprehensive molecular annotation of tumors. There is growing recognition in the clinical cancer research community that annotation of tumor specimens with data that integrates information about molecular alterations at the levels of DNA, RNA, and protein provides not only a more complete understanding of tumor biology but also provides a significant opportunity for developing new clinical tools to improve cancer treatment. Translating the knowledge gained from this molecular annotation into tools that can be used in clinical decision-making remains a major challenge. The purpose of this initiative is to build on recent demonstrations that molecular signatures correlate with important clinical parameters in cancer. The goal of this initiative is also to create publications and data sets that will be available and accessible to the scientific community in order to further the development, design, and conduct of future clinical trials (e.g., incorporation of molecular signatures into future clinical trials and large clinical validation studies) and to encourage appropriate commercialization to benefit the public health. The NCI invites investigators to form strategic partnerships that will bring together the multi-disciplinary expertise and resources needed to determine how the information derived from comprehensive molecular analyses can be used to improve patient care and, ultimately, patient outcomes.

Market-open applicant set · includes for-profit door

The eligibility set for Strategic Partnering to Evaluate Cancer Signa… includes a for-profit door among 8 printed types (State governments; Public / state-controlled institutions of higher education; Nonprofits with 501(c)(3) status (other than IHEs); Nonprofits without 501(c)(3) status (other than IHEs); +4 more). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). Only 98 other National Institutes of Health listings share this exact eligibility-code string (1% of 12,420).

Code 00
State governments
Code 06
Public / state-controlled institutions of higher education
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

What to do next

Strategic Partnering to Evaluate Cancer Signa… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 93.394;93.395 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants